Results 91 to 100 of about 53,202 (260)

Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy

Frontiers in Urology
Patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT) frequently develop cardiometabolic complications, particularly those with type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular
Sheng-Chi Huang, Wan-Yu Cheng, Cheng-You Hou, Jheng-Yan Wu, Jheng-Yan Wu, Chih-Cheng Lai, Chih-Cheng Lai, Wen-Hsin Tseng   +7 more
doaj   +1 more source

Amylin Receptor Signalling in the Laterodorsal Tegmental Nucleus Controls Food Intake Through Projections to the Ventral Tegmental Area

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The role of amylin signalling in energy balance control has been understudied in calcitonin receptor (CTR) expressing nuclei such as the mesopontine laterodorsal tegmental nucleus (LDTg). Our lab has shown that LDTg amylin signalling reduces feeding and body weight, but the neuronal phenotype and downstream targets of LDTgCTR cells ...
Marcos J. Sanchez Navarro, Carlie Zhang, Samantha M. Fortin, Matthew R. Hayes   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Luke A. Ephraums, Edward R. Mignone, Kylie Lange, Ashlee Routley, Judith Morton, Emily Hopkins, Sally Chapman, Lucia Gagliardi, Michael Horowitz, Mahesh M. Umapathysivam   +9 more
wiley   +1 more source

Energetic dysregulations in psychotic disorders: Targets for new therapeutics

The FEBS Journal, EarlyView.
The present review synthesizes literature documenting aberrant energy production and use, specifically related to mitochondrial and redox dysregulation, in psychotic disorders. Findings from different levels of investigation—genetic, cellular, and in vivo imaging—converge on aberrant energy metabolism as a hallmark of psychotic disorders.
Jacey Anderson, Kai‐Christian Sonntag, Thao Do Vy Le, Kaitlin Shannon, Chao Wang, Fei Du, Xi Chen, Donna McPhie, Dost Ongur, Bruce Cohen, Virginie‐Anne Chouinard   +10 more
wiley   +1 more source

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes

Frontiers in Pharmacology
Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications.
Yongru Chen, Jingxian Chen, Jingxian Chen, Shuo Zhang, Shuo Zhang, Dan Zhu, Feiying Deng, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou   +17 more
doaj   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity

Translation
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle changes and drug therapy can improve weight loss.
Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser   +4 more
openaire   +3 more sources

Behind GLP-1RA Use: Motivations & Mental Health

GLP-1RAs reduce food intake and body weight in humans, partly via neural circuits of appetite and reward, but the mechanisms remain unclear. In C.
Kouznetsov, Sophia
core   +2 more sources

GLP-1RAs for the treatment of obesity in women after menopause

Maturitas, 2022
Paschou, S.A., Kotsa, K., Peppa, M., Hatziagelaki, E., Psaltopoulou, T.   +4 more
openaire   +3 more sources

Association of BCAAs/BCKAs with pancreatic steatosis in patients with type 2 diabetes mellitus: A cross‐sectional study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims To examine the association between branched‐chain α‐keto acids (BCKAs) and pancreatic steatosis in patients with type 2 diabetes (T2DM). Methods This cross‐sectional study was conducted from January 2023 to March 2025. Upper abdominal computerized tomography was performed, pancreatic volume (PV), PV index (PVI), CT attenuation of pancreas
Jie Gao, Pijun Cheng, Fusong Jiang, Wenmin Li, Yingying Shi, Wenjun Wang, Liang Wang, Tao Lei, Yunxiang Zang, Jun Lu   +9 more
wiley   +1 more source